

# SB-743921

Catalog No: tcsc0233



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

940929-33-9

**Formula:**

$C_{31}H_{34}Cl_2N_2O_3$

**Pathway:**

Cytoskeleton;Cell Cycle/DNA Damage

**Target:**

Kinesin;Kinesin

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

553.52

## Product Description


SB-743921 is a potent inhibitor of the mitotic **kinesin KSP (Eg5)**, with a **K<sub>i</sub>** of 0.1 nM.

IC50 & Target: Ki: 0.1 nM (Eg5)<sup>[1]</sup>

***In Vitro:***

SB-743921 is a potent inhibitor of Eg5, with a  $K_i$  of 0.1 nM<sup>[1]</sup>. SB-743921 (1 nM) potently inhibits colony forming cell (CFC) formation of chronic myeloid leukemia (CML) primary cells, but exhibits slight inhibitory activities on the colony-forming ability of normal bone marrow progenitors. SB-743921 (1, 3 nM) induces apoptosis of CML primary CD34 + cells, and shows slight effect on normal CD34 + cells. SB-743921 (2 nM) in combination with imatinib displays additive anti-proliferative effect in KCL22 and CML CD34 + cells. Furthermore, SB-743921 overcomes imatinib resistance in CML cells. SB-743921 (0.5 nM, 1 nM, 3 nM) inhibits MEK/ERK and AKT signaling in CML cells<sup>[2]</sup>.

***In Vivo:*** SB-743921 has good oral bioavailability and pharmacokinetics and induces complete tumor regression in nude mice bearing lung cancer patient xenografts<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!